论文部分内容阅读
目的:探讨卡维地洛联合阿托伐他汀对老年慢性心力衰竭(CHF)患者心功能及外周血血浆白介素(IL)-18、IL-18结合蛋白a(IL-18BPa)、IL-37表达水平的影响。方法:选择2012年2月至2015年11月在山东省东营鸿港医院治疗的老年CHF患者162例,根据随机数字表法分为对照组和观察组,每组81例。两组均给予常规治疗,对照组在此基础上口服卡维地洛治疗,观察组在对照组基础上口服阿托伐他汀治疗。比较两组患者的临床疗效、心功能指标、外周血血浆IL-18、IL-18BPa、IL-37表达水平及不良反应发生情况。结果:观察组的治疗总有效率显著高于对照组(χ~2=8.30,P=0.004),观察组治疗后左室射血分数(LVEF)、左心室舒张末内径(LVEDD)和左心室收缩末内径(LVESD)均显著优于对照组,外周血血浆IL-18、IL-18BPa、IL-37表达水平均明显低于对照组,差异均具有统计学意义(均P<0.05)。两组患者不良反应发生率比较差异无统计学意义(χ~2=0.33,P=0.563)。结论:卡维地洛联合阿联合托伐他汀应用于老年CHF的治疗具有协同作用,可同时下调老年CHF患者外周血血浆IL-18、IL-18BPa、IL-37表达水平,共同改善患者心功能,并提升临床疗效。
Objective: To investigate the effects of carvedilol combined with atorvastatin on cardiac function and the levels of plasma interleukin (IL) -18, IL-18 binding protein-alpha (IL-18BPa) and IL-37 in elderly patients with chronic heart failure Horizontal impact. Methods: A total of 162 senile CHF patients were treated in Honggang Hospital of Dongying, Shandong Province from February 2012 to November 2015. The patients were divided into control group and observation group according to the random number table method, with 81 cases in each group. The two groups were given conventional treatment, the control group on the basis of oral carvedilol treatment, the observation group in the control group based on oral atorvastatin treatment. The clinical efficacy, cardiac function, plasma IL-18, IL-18BPa and IL-37 levels in peripheral blood and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was significantly higher than that of the control group (χ ~ 2 = 8.30, P = 0.004). The left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter The mean value of end-systolic diameter (LVESD) was significantly higher than that of the control group. The levels of IL-18, IL-18BPa and IL-37 in peripheral blood were significantly lower than those in the control group (all P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (χ ~ 2 = 0.33, P = 0.563). CONCLUSION: The combination of carvedilol and atorvastatin combined with atorvastatin has a synergistic effect on the treatment of CHF in elderly patients, which can simultaneously lower the plasma levels of IL-18, IL-18BPa and IL-37 in elderly CHF patients and jointly improve their cardiac function , And enhance clinical efficacy.